<?xml version="1.0" encoding="UTF-8"?>
<doc:document xmlns:doc="http://www.elsevier.com/xml/document/schema"
              xmlns:dp="http://www.elsevier.com/xml/common/doc-properties/schema"
              xmlns:cps="http://www.elsevier.com/xml/common/consyn-properties/schema"
              xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
              xmlns:dct="http://purl.org/dc/terms/"
              xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
              xmlns:oa="http://vtw.elsevier.com/data/ns/properties/OpenAccess-1/"
              xmlns:bam="http://vtw.elsevier.com/data/voc/ns/bam-vtw-1/"
              xmlns:cp="http://vtw.elsevier.com/data/ns/properties/Copyright-1/"
              xmlns:cja="http://www.elsevier.com/xml/cja/schema"
              xmlns:ja="http://www.elsevier.com/xml/ja/schema"
              xmlns:bk="http://www.elsevier.com/xml/bk/schema"
              xmlns:ce="http://www.elsevier.com/xml/common/schema"
              xmlns:mml="http://www.w3.org/1998/Math/MathML"
              xmlns:cals="http://www.elsevier.com/xml/common/cals/schema"
              xmlns:tb="http://www.elsevier.com/xml/common/table/schema"
              xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/schema"
              xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/schema"
              xmlns:xlink="http://www.w3.org/1999/xlink">
   <rdf:RDF>
      <rdf:Description rdf:about="http://dx.doi.org/10.1016/j.phyplu.2022.100225">
         <dct:format>application/xml</dct:format>
         <dct:title>Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy</dct:title>
         <dct:creator>Anuj Kumar Borah</dct:creator>
         <dct:creator>Semim Akhtar Ahmed</dct:creator>
         <dct:creator>Jagat C. Borah</dct:creator>
         <dct:subject>
            <rdf:Bag>
               <rdf:li>Diabetic nephropathy</rdf:li>
               <rdf:li>GLP-1 secretagogues</rdf:li>
               <rdf:li>DPP-IV inhibitors</rdf:li>
               <rdf:li>SGLT2 inhibitors</rdf:li>
               <rdf:li>Herbal medicine and incretin modulators</rdf:li>
            </rdf:Bag>
         </dct:subject>
         <dct:description>Phytomedicine Plus 2 (2022). doi:10.1016/j.phyplu.2022.100225</dct:description>
         <prism:aggregationType>journal</prism:aggregationType>
         <prism:publicationName>Phytomedicine Plus</prism:publicationName>
         <prism:copyright>© 2022 The Author(s). Published by Elsevier B.V.</prism:copyright>
         <dct:publisher>Elsevier B.V.</dct:publisher>
         <prism:issn>2667-0313</prism:issn>
         <prism:volume>2</prism:volume>
         <prism:number>2</prism:number>
         <prism:coverDisplayDate>May 2022</prism:coverDisplayDate>
         <prism:doi>10.1016/j.phyplu.2022.100225</prism:doi>
         <prism:url>http://dx.doi.org/10.1016/j.phyplu.2022.100225</prism:url>
         <dct:identifier>doi:10.1016/j.phyplu.2022.100225</dct:identifier>
         <bam:articleNumber>100225</bam:articleNumber>
         <oa:openAccessInformation>
            <oa:openAccessStatus xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://vtw.elsevier.com/data/voc/oa/OpenAccessStatus#Full</oa:openAccessStatus>
            <oa:openAccessEffective xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">2022-01-15T06:36:10Z</oa:openAccessEffective>
            <oa:sponsor xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
               <oa:sponsorType>http://vtw.elsevier.com/data/voc/oa/SponsorType#Author</oa:sponsorType>
            </oa:sponsor>
            <oa:userLicense xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://creativecommons.org/licenses/by/4.0/</oa:userLicense>
         </oa:openAccessInformation>
         <cp:licenseLine xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">This is an open access article under the CC BY license.</cp:licenseLine>
      </rdf:Description>
   </rdf:RDF>
   <dp:document-properties>
      <dp:aggregation-type>Journals</dp:aggregation-type>
      <dp:version-number>S250.1</dp:version-number>
   </dp:document-properties>
   <ja:article docsubtype="rev" version="5.6" xml:lang="en">
      <ja:item-info>
         <ja:jid>PHYPLU</ja:jid>
         <ja:aid>100225</ja:aid>
         <ce:article-number>100225</ce:article-number>
         <ce:pii>S2667-0313(22)00011-2</ce:pii>
         <ce:doi>10.1016/j.phyplu.2022.100225</ce:doi>
         <ce:copyright type="other" year="2022">The Author(s)</ce:copyright>
      </ja:item-info>
      <ja:head>
         <ce:title id="tte0002">Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy</ce:title>
         <ce:author-group id="aut0001">
            <ce:author id="au0001"
                       author-id="S2667031322000112-b5bc00afa82eeae8dbb5bcae4f973585">
               <ce:given-name>Anuj Kumar</ce:given-name>
               <ce:surname>Borah</ce:surname>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/data-curation">Data curation</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/writing-original-draft">Writing – original draft</ce:contributor-role>
               <ce:cross-ref refid="aff0002">
                  <ce:sup loc="post">b</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0002"
                       author-id="S2667031322000112-ffc26ed31133c1fbf777824d5d8a257a">
               <ce:given-name>Semim Akhtar</ce:given-name>
               <ce:surname>Ahmed</ce:surname>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/data-curation">Data curation</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/writing-original-draft">Writing – original draft</ce:contributor-role>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="aff0003">
                  <ce:sup loc="post">c</ce:sup>
               </ce:cross-ref>
            </ce:author>
            <ce:author id="au0003"
                       author-id="S2667031322000112-637061bb924d6608cedc958deac18de4">
               <ce:given-name>Jagat C.</ce:given-name>
               <ce:surname>Borah</ce:surname>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/data-curation">Data curation</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/supervision">Supervision</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/writing-review-editing">Writing – review &amp; editing</ce:contributor-role>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="aff0003">
                  <ce:sup loc="post">c</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="cor0001">
                  <ce:sup loc="post">⁎</ce:sup>
               </ce:cross-ref>
               <ce:e-address id="ead0001" type="email" xlink:href="mailto:borahjc@gmail.com">borahjc@gmail.com</ce:e-address>
            </ce:author>
            <ce:affiliation id="aff0001"
                            affiliation-id="S2667031322000112-9b7fe0ef8d3c2adbb72046cc7f16bbfd">
               <ce:label>a</ce:label>
               <ce:textfn id="cetextfn0001">Laboratory of Chemical Biology, Life Sciences Division, Institute of Advanced Study in Science &amp; Technology, Guwahati 781035, Assam, India</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Laboratory of Chemical Biology, Life Sciences Division</sa:organization>
                  <sa:organization>Institute of Advanced Study in Science &amp; Technology</sa:organization>
                  <sa:city>Guwahati</sa:city>
                  <sa:state>Assam</sa:state>
                  <sa:postal-code>781035</sa:postal-code>
                  <sa:country>India</sa:country>
               </sa:affiliation>
               <ce:source-text id="staff0001">aLaboratory of Chemical Biology, Life Sciences Division, Institute of Advanced Study in Science &amp; Technology, Guwahati 781035, Assam, India</ce:source-text>
            </ce:affiliation>
            <ce:affiliation id="aff0002"
                            affiliation-id="S2667031322000112-c84855a3d33c02ba11c82bc8f9b532ad">
               <ce:label>b</ce:label>
               <ce:textfn id="cetextfn0002">Brilliant Academy, North Lakhimpur, Lakhimpur, Assam 787001, India</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Brilliant Academy</sa:organization>
                  <sa:address-line>North Lakhimpur</sa:address-line>
                  <sa:city>Lakhimpur</sa:city>
                  <sa:state>Assam</sa:state>
                  <sa:postal-code>787001</sa:postal-code>
                  <sa:country>India</sa:country>
               </sa:affiliation>
               <ce:source-text id="staff0002">bBrilliant Academy, North Lakhimpur, Lakhimpur, Assam 787001, India</ce:source-text>
            </ce:affiliation>
            <ce:affiliation id="aff0003"
                            affiliation-id="S2667031322000112-8bc4d650c102742e69ca1ba717e4d494">
               <ce:label>c</ce:label>
               <ce:textfn id="cetextfn0003">Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Academy of Scientific and Innovative Research (AcSIR)</sa:organization>
                  <sa:city>Ghaziabad</sa:city>
                  <sa:country>India</sa:country>
               </sa:affiliation>
               <ce:source-text id="staff0003">cAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad, India</ce:source-text>
            </ce:affiliation>
            <ce:correspondence id="cor0001">
               <ce:label>⁎</ce:label>
               <ce:text id="cetext0001">Corresponding author at: Jagat Chandra Borah, Ph.D. Laboratory of Chemical Biology, Life Sciences Division, Institute of Advanced Study in Science &amp; Technology, Guwahati 781035, Assam, India.</ce:text>
               <sa:affiliation>
                  <sa:organization>Laboratory of Chemical Biology, Life Sciences Division</sa:organization>
                  <sa:organization>Institute of Advanced Study in Science &amp; Technology</sa:organization>
                  <sa:city>Guwahati</sa:city>
                  <sa:state>Assam</sa:state>
                  <sa:postal-code>781035</sa:postal-code>
                  <sa:country>India</sa:country>
               </sa:affiliation>
            </ce:correspondence>
         </ce:author-group>
         <ce:date-received day="22" month="9" year="2021"/>
         <ce:date-revised day="4" month="1" year="2022"/>
         <ce:date-accepted day="15" month="1" year="2022"/>
         <ce:abstract id="abs0001" class="author-highlights" view="all">
            <ce:section-title id="cesectitle0001">Highlights</ce:section-title>
            <ce:abstract-sec id="abss0001" view="all">
               <ce:simple-para id="spara010" view="all">
                  <ce:list id="celist0001">
                     <ce:list-item id="celistitem0001">
                        <ce:label>•</ce:label>
                        <ce:para id="para0001" view="all">Chronic kidney disease (CKD), end stage renal disease (ESRD), and cardiovascular risks are hazardous consequences of diabetic nephropathy (DN).</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0002">
                        <ce:label>•</ce:label>
                        <ce:para id="para0002" view="all">Incretin modulators and SGLT2 inhibitors are appealing and favorable outlook beyond RAAS modulation investigated for mitigation of DN.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0003">
                        <ce:label>•</ce:label>
                        <ce:para id="para0003" view="all">Phyto-preparations are gaining ever increasing therapeutic importance unpinned by their multiple benefits in DN.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0004">
                        <ce:label>•</ce:label>
                        <ce:para id="para0004" view="all">Phyto-preparations stand as unmatched plausible sources of natural incretin modulators and SGLT2 inhibitors towards combating DN.</ce:para>
                     </ce:list-item>
                  </ce:list>
               </ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:abstract id="abs0002" view="all" class="author">
            <ce:section-title id="cesectitle0002">Abstract</ce:section-title>
            <ce:abstract-sec id="abss0003" role="background" view="all">
               <ce:section-title id="cesectitle0003">Background</ce:section-title>
               <ce:simple-para id="spara011" view="all">Diabetic nephropathy (DN) has been the major contributor to chronic kidney disease (CKD), end stage renal disease (ESRD), and cardiovascular risks. Incretin pathway modulators (GLP-1 analogs, GLP-1R agonist, GLP-1 secretagogues and DPP-IV inhibitors) and SGLT2 inhibitors are presently the favourable outlooks among the numerous therapeutic approaches and efforts considered for DN beyond RAAS modulation.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0004" view="all">
               <ce:section-title id="cesectitle0004">Purpose</ce:section-title>
               <ce:simple-para id="spara012" view="all">The current state of art is an attempt to mine and demonstrate extant knowledge of plausible plant source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors towards mitigation of DN.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0005" role="materials-methods" view="all">
               <ce:section-title id="cesectitle0005">Methods</ce:section-title>
               <ce:simple-para id="spara013" view="all">Scientific search engines PubMed, Google Scholar, Scopus, and SciFinder are accessed towards collecting literatures on pathophysiology of DN, treatment regimens, herbs for DN, and available literatures regarding plant sources of SGLT2 inhibitors and incretin modulators.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0006" role="results" view="all">
               <ce:section-title id="cesectitle0006">Results</ce:section-title>
               <ce:simple-para id="spara014" view="all">This literature review has comprehensively collated, critically analyzed, and documented the state of art phyto-preparations and phytocompounds based strategies for management of DN. GLP-1 secretagogues activity, DPP-IV and SGLT2 inhibitory activity elicited from plant -based compounds have been extensively reviewed. The literature on mechanism of action, dose and principles of the treatments, and the degree of evidence for plant derived formulations have been rigorously examined and critiqued. Consequently, the review has brought into focus that the bioactive principle of many of the effective investigated phyto-preparations with potential against DN are yet to be discovered. It is also revealed the need of toxicological safety assessment and effectiveness <ce:italic>in vivo</ce:italic> investigation for many of the plant preparations and plant compound demonstrating <ce:italic>in vitro</ce:italic> potential against DN towards availing effective, safer and economically sound alternatives to synthetic incretin modulators and SGLT2 inhibitors.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0007" role="conclusion" view="all">
               <ce:section-title id="cesectitle0007">Conclusion</ce:section-title>
               <ce:simple-para id="spara015" view="all">The extant literature reviewed in the present article provides a good scope to further investigate in-depth mechanistic aspects of phytomedicine reported for DN management. The reviewed literatures suggest that <ce:italic>in vivo</ce:italic> investigations can be made with toxicologically safe phytomedicine and plant derived incretin modulators, and SGLT2 inhibitors having excellent therapeutic potential against DN. Further, this review endeavors to bolster research into plant based alternatives that are comparatively safe and less costly, to augment extant state of art incretin modulators and SGLT2 inhibitors.</ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:abstract id="abs0003" class="graphical" view="all">
            <ce:section-title id="cesectitle0008">Graphical abstract</ce:section-title>
            <ce:abstract-sec id="abss0008" view="all">
               <ce:simple-para id="spara016" view="all"> [Display omitted] </ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:keywords id="keys0001" view="all" class="keyword">
            <ce:section-title id="cesectitle0009">Keywords</ce:section-title>
            <ce:keyword id="key0001">
               <ce:text id="cetext0002">Diabetic nephropathy</ce:text>
            </ce:keyword>
            <ce:keyword id="key0002">
               <ce:text id="cetext0003">GLP-1 secretagogues</ce:text>
            </ce:keyword>
            <ce:keyword id="key0003">
               <ce:text id="cetext0004">DPP-IV inhibitors</ce:text>
            </ce:keyword>
            <ce:keyword id="key0004">
               <ce:text id="cetext0005">SGLT2 inhibitors</ce:text>
            </ce:keyword>
            <ce:keyword id="key0005">
               <ce:text id="cetext0006">Herbal medicine and incretin modulators</ce:text>
            </ce:keyword>
         </ce:keywords>
      </ja:head>
   </ja:article>
</doc:document>
